Adalvo is on target to file the Ruxolitinib Immediate Release (IR) Tablets dossier in Q4 2024.
Filing upon dossier readiness, Adalvo aims to be among the first companies to launch this product to market on Day-1.
Ruxolitinib is the first FDA-approved prescription medicine for adults with Polycythemia Vera and Myelofibrosis and has also gained a significant presence in Europe.
Adalvo is among the few companies advancing the development of a range of Ruxolitinib formulations, including both IR and ER tablets.
With a clearly defined IP strategy, this dossier presents a first-to-market opportunity in all major markets.
In 2023, Ruxolitinib IR contributed to a global MAT sale of $2Bn with a 3Y CAGR of 5%, according to IQVIA.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!